Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Affymax, Inc. (AFFY)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
630 Fifth Avenue 10020
New York City, NY, US
New York City, NY, US
CEO
Jonathan Couchman
Website
affymax.com
IPO
2006-12-15
ISIN US00826A1097
Description
Affymax, Inc. presently lacks any substantial operational activities. In its earlier history, the firm concentrated on the creation of pharmaceutical agents designed to improve therapies for severe and frequently fatal health issues across the United States. Established in 2001, its corporate base is situated in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.2K
Beta
7.32
Float Shares
36.96M
Free Float %
98.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +11.11% | +25.00% | +25.00% | -75.61% | -98.46% | -98.67% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Hold
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
0.11
+10,772.8%
DCF (Levered)
0.11
+10,472.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-145.85
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-98.6% Q2'14: -92.0% (vs Q2'13)
-
EPS growth Biotechnology: +29.7%+84.8% ★ Q2'14: -53.7% (vs Q2'13)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,473.6% Q2'14: -3,469.0% (vs Q2'13)
-
EBIT margin Biotechnology: +0.0%-1,096.9% Q2'14: -2,438.1% (vs Q2'13)
-
ROIC Biotechnology: -16.1%— Q2'14: -229.0% (vs Q2'13)
-
Share dilution Biotechnology: -3.4%+3.0% ★ Q2'14: 0.0% (vs Q2'13)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q2'14: 0.00× (vs Q2'13)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2013 actual |
Dec 2014 actual |
|---|---|---|
| Revenue |
1.37M
est: 1.37M (+0.0%)
|
13.68M
est.
|
| EBITDA |
-14.30M
est: -1.02M (-1,304.9%)
|
-10.17M
est.
|
| EBIT |
-15.02M
est: -1.03M (-1,352.5%)
|
-10.33M
est.
|
| Net Income |
-14.42M
|
—
est.
|
| SGA |
27.53M
est: 6.12M (+349.6%)
|
61.19M
est.
|
| EPS |
-0.39
|
—
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.97M
OE per share TTM
-0.27
Owner's Yield
-26,593.22%
Maintenance CapEx ratio
0.36%
Maint CapEx / Avg PPE
5.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-08-28 | WALKER JOHN PETER | Director | S-Sale | D | Common Stock | 16,040 | 1.92 | 30.8K | 500 | — | ↗ |
| 2013-06-28 | Orwin John A | Director | G-Gift | D | Common Stock | 15,000 | 0.00 | — | 76,666 | — | ↗ |
| 2013-06-27 | Orwin John A | Director | F-InKind | D | Common Stock | 16,334 | 1.02 | 16.7K | 91,666 | — | ↗ |
| 2013-02-15 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 1,015 | 6.23 | 6.3K | 20,453 | — | ↗ |
| 2013-02-01 | Orwin John A | Director / Officer | S-Sale | D | Common Stock | 6,366 | 18.81 | 119.7K | 108,000 | — | ↗ |
| 2013-01-30 | Orwin John A | Director / Officer | A-Award | A | Common Stock | 16,000 | 0.00 | — | 108,000 | — | ↗ |
| 2013-01-30 | Knapp Jeffrey H | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 19.43 | 582.9K | 30,000 | — | ↗ |
| 2013-01-15 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 1,016 | 6.23 | 6.3K | 17,891 | — | ↗ |
| 2012-12-17 | Knapp Jeffrey H | Officer | S-Sale | D | Common Stock | 6,694 | 22.31 | 149.3K | 13,125 | — | ↗ |
| 2012-12-03 | Orwin John A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,498 | 6.90 | 86.2K | 162,513 | — | ↗ |
| 2012-11-19 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,000 | 21.74 | 21.7K | 6,000 | — | ↗ |
| 2012-11-15 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,099 | 10.99 | 12.1K | 1,167 | — | ↗ |
| 2012-10-15 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,584 | 10.99 | 17.4K | 2,266 | — | ↗ |
| 2012-10-10 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 14,100 | 24.50 | 345.5K | 28,139 | — | ↗ |
| 2012-10-09 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 21.74 | 260.9K | 8,000 | — | ↗ |
| 2012-10-05 | Orwin John A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 41,664 | 6.90 | 287.5K | 175,011 | — | ↗ |
| 2012-10-01 | Orwin John A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,332 | 6.90 | 57.5K | 216,675 | — | ↗ |
| 2012-09-17 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 1,015 | 6.23 | 6.3K | 20,388 | — | ↗ |
| 2012-09-13 | Orwin John A | Director / Officer | M-Exempt | A | Common Stock | 37,497 | 6.90 | 258.7K | 129,497 | — | ↗ |
| 2012-09-13 | Knapp Jeffrey H | Officer | S-Sale | D | Common Stock | 19,663 | 20.00 | 393.3K | 14,039 | — | ↗ |
| 2012-08-20 | Orwin John A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,500 | 5.83 | 67.0K | 57,000 | — | ↗ |
| 2012-08-20 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,313 | 10.99 | 58.4K | 5,434 | — | ↗ |
| 2012-08-15 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 3,000 | 6.23 | 18.7K | 20,769 | — | ↗ |
| 2012-08-13 | Knapp Jeffrey H | Officer | S-Sale | D | Common Stock | 4,659 | 15.95 | 74.3K | 17,769 | — | ↗ |
| 2012-08-01 | Orwin John A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,100 | 5.83 | 6.4K | 68,500 | — | ↗ |
| 2012-07-16 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 6.23 | 18.7K | 36,750 | — | ↗ |
| 2012-07-13 | Orwin John A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,200 | 5.83 | 12.8K | 69,600 | — | ↗ |
| 2012-07-13 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 4,752 | 10.99 | 52.2K | 28,093 | — | ↗ |
| 2012-06-15 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 3,000 | 6.23 | 18.7K | 26,341 | — | ↗ |
| 2012-06-13 | van Heek Christi | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 12.82 | 153.8K | 12,000 | — | ↗ |
| 2012-06-13 | WALKER JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 12.82 | 153.8K | 12,000 | — | ↗ |
| 2012-06-13 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 12.82 | 153.8K | 12,000 | — | ↗ |
| 2012-06-13 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 12.82 | 153.8K | 12,000 | — | ↗ |
| 2012-06-13 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 12.82 | 153.8K | 12,000 | — | ↗ |
| 2012-06-13 | LOVE TED W | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 12.82 | 153.8K | 12,000 | — | ↗ |
| 2012-05-15 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 6.23 | 18.7K | 42,750 | — | ↗ |
| 2012-04-27 | Orwin John A | Director / Officer | S-Sale | D | Common Stock | 30,000 | 13.35 | 400.6K | 108,500 | — | ↗ |
| 2012-04-24 | Knapp Jeffrey H | Officer | M-Exempt | A | Common Stock | 1,500 | 6.23 | 9.3K | 25,755 | — | ↗ |
| 2012-04-16 | Knapp Jeffrey H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,500 | 6.23 | 9.3K | 47,250 | — | ↗ |
| 2012-04-03 | Orwin John A | Director / Officer | S-Sale | D | Common Stock | 16,500 | 11.93 | 196.8K | 138,500 | — | ↗ |
| 2012-03-27 | Orwin John A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,200 | 5.83 | 47.8K | 71,800 | — | ↗ |
| 2012-03-27 | Knapp Jeffrey H | Officer | — | D | Common Stock | 0 | 0.00 | — | 25,169 | — | ↗ |
| 2012-02-02 | Orwin John A | Director / Officer | S-Sale | D | Common Stock | 18,000 | 10.00 | 180.0K | 155,000 | — | ↗ |
| 2012-01-31 | Orwin John A | Director / Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 173,000 | — | ↗ |
| 2011-12-19 | WALKER JOHN PETER | Director | P-Purchase | A | Common Stock | 14,000 | 6.09 | 85.3K | 16,540 | — | ↗ |
| 2011-08-18 | Orwin John A | Director / Officer | S-Sale | D | Common Stock | 12,000 | 4.55 | 54.6K | 148,000 | — | ↗ |
| 2011-05-25 | van Heek Christi | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 6.86 | 82.3K | 12,000 | — | ↗ |
| 2011-05-25 | WALKER JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 6.86 | 82.3K | 12,000 | — | ↗ |
| 2011-05-25 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 6.86 | 82.3K | 12,000 | — | ↗ |
| 2011-05-25 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 6.86 | 82.3K | 12,000 | — | ↗ |
| 2011-05-25 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 6.86 | 82.3K | 12,000 | — | ↗ |
| 2011-05-25 | LOVE TED W | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 6.86 | 82.3K | 12,000 | — | ↗ |
| 2011-02-01 | Orwin John A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 6.90 | 2.07M | 300,000 | — | ↗ |
| 2010-09-22 | Orwin John A | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 5.83 | 466.4K | 80,000 | — | ↗ |
| 2010-08-09 | CREDIT SUISSE AG/ | 10% Owner | S-Sale | A | Common Stock | 450,000 | 7.83 | 3.52M | 1,774,407 | — | ↗ |
| 2010-05-24 | van Heek Christi | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 22.93 | 172.0K | 7,500 | — | ↗ |
| 2010-05-24 | WALKER JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 22.93 | 172.0K | 7,500 | — | ↗ |
| 2010-05-24 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 22.93 | 172.0K | 7,500 | — | ↗ |
| 2010-05-24 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 22.93 | 172.0K | 7,500 | — | ↗ |
| 2010-05-24 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 22.93 | 172.0K | 7,500 | — | ↗ |
| 2010-05-24 | LOVE TED W | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 22.93 | 172.0K | 7,500 | — | ↗ |
| 2010-05-24 | Douglas R Lee | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 22.93 | 172.0K | 7,500 | — | ↗ |
| 2010-04-12 | Orwin John A | Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 22.70 | 4.99M | 220,000 | — | ↗ |
| 2009-06-09 | RENTON HOLLINGS | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 16.58 | 124.4K | 7,500 | — | ↗ |
| 2009-05-28 | van Heek Christi | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 16.79 | 42.0K | 2,500 | — | ↗ |
| 2009-05-28 | WALKER JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 16.79 | 42.0K | 2,500 | — | ↗ |
| 2009-05-28 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 16.79 | 42.0K | 2,500 | — | ↗ |
| 2009-05-28 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 16.79 | 42.0K | 2,500 | — | ↗ |
| 2009-05-28 | LOVE TED W | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 16.79 | 42.0K | 2,500 | — | ↗ |
| 2009-05-28 | Douglas R Lee | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 16.79 | 42.0K | 2,500 | — | ↗ |
| 2009-03-02 | CREDIT SUISSE/ | 10% Owner | P-Purchase | A | Common Stock | 652,262 | 15.25 | 9.95M | 2,224,407 | — | ↗ |
| 2008-05-22 | van Heek Christi | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 14.24 | 35.6K | 2,500 | — | ↗ |
| 2008-05-22 | WALKER JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 14.24 | 35.6K | 2,500 | — | ↗ |
| 2008-05-22 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 14.24 | 35.6K | 2,500 | — | ↗ |
| 2008-05-22 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 14.24 | 35.6K | 2,500 | — | ↗ |
| 2008-05-22 | LOVE TED W | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 14.24 | 35.6K | 2,500 | — | ↗ |
| 2008-05-22 | Douglas R Lee | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 14.24 | 35.6K | 2,500 | — | ↗ |
| 2007-12-06 | van Heek Christi | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 25.83 | 193.7K | 7,500 | — | ↗ |
| 2007-12-06 | Leonard Keith R | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 25.83 | 193.7K | 7,500 | — | ↗ |
| 2007-12-03 | NASO ROBERT B | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,803 | 0.80 | 3.8K | 2,167 | — | ↗ |
| 2007-11-01 | NASO ROBERT B | Officer | S-Sale | D | Common Stock | 984 | 28.34 | 27.9K | 4,986 | — | ↗ |
| 2007-09-19 | NASO ROBERT B | Officer | S-Sale | D | Common Stock | 1,900 | 27.39 | 52.0K | 15,228 | — | ↗ |
| 2007-09-18 | NASO ROBERT B | Officer | S-Sale | D | Common Stock | 200 | 27.20 | 5.4K | 12,493 | — | ↗ |
| 2007-09-17 | NASO ROBERT B | Officer | S-Sale | D | Common Stock | 200 | 27.81 | 5.6K | 6,000 | — | ↗ |
| 2007-05-31 | WALKER JOHN PETER | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 32.89 | 82.2K | 2,500 | — | ↗ |
| 2007-05-31 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 32.89 | 82.2K | 2,500 | — | ↗ |
| 2007-05-31 | LOVE TED W | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 32.89 | 82.2K | 2,500 | — | ↗ |
| 2007-05-31 | Douglas R Lee | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 32.89 | 82.2K | 2,500 | — | ↗ |
| 2007-01-05 | NASO ROBERT B | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 33.97 | 2.72M | 80,000 | — | ↗ |
| 2006-12-20 | MPM BioVentures Strategic Fund LP | 10% Owner | C-Conversion | D | Series B Convertible Preferred Stock | 350,000 | 0.00 | — | 0 | — | ↗ |
| 2006-12-20 | MPM BIOVENTURES II QP LP | 10% Owner | C-Conversion | D | Series C Convertible Preferred Stock | 554,727 | 0.00 | — | 0 | — | ↗ |
| 2006-12-20 | CREDIT SUISSE/ | 10% Owner | C-Conversion | A | Common Stock | 331,301 | 0.00 | — | 1,572,145 | — | ↗ |
| 2006-12-20 | BEAR STEARNS COMPANIES INC | 10% Owner | C-Conversion | A | Common Stock | 496,950 | 0.00 | — | 1,159,551 | — | ↗ |
| 2006-12-19 | MPM BioVentures Strategic Fund LP | 10% Owner | X-InTheMoney | A | Common Stock | 107,266 | 17.00 | 1.82M | 138,514 | — | ↗ |
| 2006-12-19 | MPM BIOVENTURES II QP LP | 10% Owner | X-InTheMoney | D | Warrant (Right to Buy) | 107,266 | 17.00 | 1.82M | 0 | — | ↗ |
| 2006-12-14 | WALKER JOHN PETER | Director | — | D | no securities held | 0 | 0.00 | — | 0 | — | ↗ |
| 2006-12-14 | MPM BioVentures Strategic Fund LP | 10% Owner | — | I | Warrant (right to buy) | 107,266 | 17.00 | 1.82M | 0 | — | ↗ |
| 2006-12-14 | MPM BIOVENTURES II QP LP | 10% Owner | — | I | Series C Convertible Preferred Stock | 554,727 | 0.00 | — | 0 | — | ↗ |
| 2006-12-14 | Douglas R Lee | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 25.00 | 187.5K | 7,500 | — | ↗ |
| 2006-12-14 | CREDIT SUISSE/ | 10% Owner | — | I | Series B Convertible Preferred Stock | 516,348 | 0.00 | — | 0 | — | ↗ |
| 2006-12-14 | BEAR STEARNS COMPANIES INC | 10% Owner | — | I | Series C Convertible Preferred Stock | 662,601 | 0.00 | — | 0 | — | ↗ |
| 2006-07-28 | SPIEGELMAN DANIEL K | Director | — | D | Stock Option (Right to Buy) | 7,500 | 18.84 | 141.3K | 0 | — | ↗ |
| 2006-07-28 | LOVE TED W | Director | — | D | Stock Option (Right to Buy) | 7,500 | 18.84 | 141.3K | 0 | — | ↗ |
| 2006-02-10 | NASO ROBERT B | Officer | — | D | Stock Option (Right to Buy) | 63,999 | 4.36 | 279.0K | 0 | — | ↗ |
| 2006-02-10 | Douglas R Lee | Director | — | D | Stock Option (right to Buy) | 7,500 | 4.36 | 32.7K | 0 | — | ↗ |
| 2004-12-15 | NASO ROBERT B | Officer | — | D | Stock Option (Right to Buy) | 8,000 | 0.80 | 6.4K | 0 | — | ↗ |
| 2004-08-05 | Douglas R Lee | Director | — | D | Stock Option (Right to Buy) | 16,250 | 0.80 | 13.0K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-75.1K
Shares Outstanding
37.49M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark G. Thompson | Chief Financial Officer & Secretary | 97.5K | male |
| Jonathan Couchman | Chief Executive Officer, President & Director | — | male |
| Tracy J. Dunn | Vice President of Intellectual Property & Legal Affairs | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AFFY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
